Chardan Capital Boosts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $91.00

Intellia Therapeutics (NASDAQ:NTLA) had its price target upped by analysts at Chardan Capital from $88.00 to $91.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

NTLA has been the subject of several other research reports. Barclays decreased their price target on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a research report on Friday, November 8th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a research note on Friday, November 8th. Citigroup reduced their price target on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. The Goldman Sachs Group lowered their price objective on Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Finally, Robert W. Baird reduced their target price on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.94.

Intellia Therapeutics Trading Down 0.3 %

Shares of NASDAQ NTLA opened at $14.13 on Monday. The stock has a fifty day simple moving average of $18.52 and a 200-day simple moving average of $21.97. Intellia Therapeutics has a twelve month low of $13.54 and a twelve month high of $34.87. The stock has a market capitalization of $1.44 billion, a PE ratio of -2.60 and a beta of 1.81.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to analysts’ expectations of $8.28 million. The firm’s revenue for the quarter was down 24.1% on a year-over-year basis. During the same quarter last year, the company earned ($1.38) earnings per share. On average, equities analysts predict that Intellia Therapeutics will post -5.13 earnings per share for the current year.

Insider Activity

In other news, CAO Michael P. Dube sold 2,012 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the sale, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This represents a 4.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 3.20% of the company’s stock.

Institutional Trading of Intellia Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in NTLA. First Horizon Advisors Inc. grew its stake in shares of Intellia Therapeutics by 22.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after purchasing an additional 472 shares during the last quarter. Elmwood Wealth Management Inc. grew its position in Intellia Therapeutics by 0.9% in the 3rd quarter. Elmwood Wealth Management Inc. now owns 67,774 shares of the company’s stock valued at $1,393,000 after buying an additional 600 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Intellia Therapeutics by 27.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after buying an additional 794 shares during the period. Capstone Investment Advisors LLC raised its position in Intellia Therapeutics by 1.4% during the 3rd quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company’s stock worth $1,256,000 after buying an additional 831 shares during the last quarter. Finally, Axxcess Wealth Management LLC lifted its stake in shares of Intellia Therapeutics by 6.5% in the 1st quarter. Axxcess Wealth Management LLC now owns 16,602 shares of the company’s stock worth $457,000 after acquiring an additional 1,010 shares during the period. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.